KUALA LUMPUR: CCM Duopharma Biotech Bhd
(CCMD) and South Korea’s PanGen Biotech will conduct phase three clinical trials of the latter’s PDA10 drug to treat patients with anemia due to chronic kidney failure.
CCMD said on Friday if the trials, starting in November are successful, it will have the commercialisation rights to market and distribute the drug in Malaysia, Singapore and Brunei, worth more than RM50mil annually.
